Table 3.
Details regarding characteristics of participants
| Characteristics of participant (baseline characteristics) | n (%) |
|---|---|
| Follow-up periods between the last dose of the medication and the interview date | |
| 2 months | 421 (42) |
| 1 month and 3 weeks | 488 (49) |
| 1 month and 2 weeks | 73 (7) |
| 1 month and 1 week | 12 (1) |
| <1 month and 1 week but >2 weeks | 9 (1) |
| Age of participant (years) | |
| 18-20 | 5 (0.5) |
| 21-30 | 249 (24.8) |
| 31-40 | 279 (27.8) |
| 41-50 | 338 (33.7) |
| 51-60 | 125 (12.5) |
| 61-70 | 7 (0.7) |
| Sex of the participants | |
| Male | 904 (90.1) |
| Female | 99 (9.9) |
| Distribution of participants according to occupation | |
| Guards | 17 (1.6) |
| Health professionals | 69 (6.9) |
| Others | 135 (13.5) |
| Police personals | 782 (78.0) |
| Preexisting conditions in the participants prior to intake of medications | 46 (4.6) |
| Influenza-like symptoms | |
| Cough and cold | 30 (3.0) |
| Fever | 8 (0.8) |
| Body ache | 6 (0.6) |
| Headache | 4 (0.4) |
| Weakness | 3 (0.3) |
| Hypertension | 3 (0.3) |
| DM2 | 2 (0.2) |
| Hemorrhoids | 2 (0.2) |
| Constipation | 2 (0.2) |
| Asthma | 1 (0.1) |
|
| |
| Symptoms observed in participants after intake of kits | |
|
| |
| Adverse reaction observed by the participants | |
| Vertigo | 1 (0.1) |
| Body ache | 2 (0.2) |
| Headache | 3 (0.3) |
| Excessive perspiration and burning sensation in body | 15 (1.5) |
| Obstructed flow of urination/burning micturition | 3 (0.3) |
| Acne | 4 (0.4) |
| Gastrointestinal tract-related symptoms | |
| Aphthous ulcer | 2 (0.2) |
| Nausea and vomiting | 7 (0.7) |
| Acidity and burning sensation in abdomen | 13 (1.3) |
| Diarrhea | 4 (0.4) |
| Constipation | 6 (0.6) |
| Bleeding per rectum | 2 (0.2) |
DM: Diabetes mellitus